Last reviewed · How we verify

NCT06215300

The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.

Status unknown Last updated 22 January 2024
What this trial tests

trial testing coronary artery bypass grafting in to Evaluate the Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier on the Development of Cardiovascular Events After Coronary Artery Bypass Grafting in 800 participants. Status unknown.

Timeline
1 December 2022
Primary endpoint
1 November 2025
1 November 2025

Quick facts

Lead sponsorNovosibirsk Scientific Research Institute for Circulatory Pathology
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment800
Start date1 December 2022
Primary completion1 November 2025
Estimated completion1 November 2025
Sites2 locations across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Novosibirsk Scientific Research Institute for Circulatory Pathology

Who can join

Adults 18 to 90, any sex, with to Evaluate the Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier on the Development of Cardiovascular Events After Coronary Artery Bypass Grafting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Polymorphism in the GUCY1A3 gene worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. Studies have shown the association of the GUCY1A3 gene with the risk of coronary heart disease and its complications, with ischemic stroke

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of coronary artery bypass grafting

Trials testing the same drug.

Other Novosibirsk Scientific Research Institute for Circulatory Pathology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06215300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing